JNGLX: Janus Henderson Global Life Sciences D

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

JNGLX Janus Henderson Global Life Sciences D

  • Fund
  • JNGLX
  • Price as of: Dec 12, 2019
  • $63.62
    + $0.50 + 0.79%

Profile

JNGLX - Profile

Vitals

  • YTD Return 26.1%
  • 3 Yr Annualized Return 16.2%
  • 5 Yr Annualized Return 9.0%
  • Net Assets $4.02 B
  • Holdings in Top 10 32.2%

52 WEEK LOW AND HIGH

$63.62
$47.36
$63.62

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.82%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 36.00%

TRADING FEES

  • Max Redemption Fee 2.00%

Min Investment

Closed to new investors as of Feb 12, 2010
  • Standard (Taxable) $2,500
  • IRA $1,000

Fund Classification


Distributions

  • YTD Total Return 26.1%
  • 3 Yr Annualized Total Return 16.2%
  • 5 Yr Annualized Total Return 9.0%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio 0.48%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Semi-Annually

Fund Details

  • Legal Name
    Janus Henderson Global Life Sciences Fund
  • Fund Family Name
    Janus Henderson
  • Inception Date
    Dec 31, 1998
  • Shares Outstanding
    N/A
  • Share Class
    D
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Andrew Acker

Fund Description

The Janus Global Life Sciences Fund Class D (JNGLX) is a low-cost, actively managed fund focused on the health care sector. The fund holds a wide range of health care-related equities from around the world and can invest in any market-cap size. JNGLX balances its investments in the biotech, traditional pharmaceuticals and health care equipment/services sphere in order to help reduce volatility.

As a specialized health care fund, JNGLX should only be used as a satellite position in a broader equity portfolio. The fund is managed by Janus Capital Management.


Get Updates About JNGLX

Sign up for Advisor Access to receive email updates about JNGLX competitors, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Categories

Fund Company Quick Screens

JNGLX - Fund Company Quick Screens


Performance

JNGLX - Performance

Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 26.1% 3.4% 49.1% 21.37%
1 Yr 13.0% -12.6% 29.3% 26.50%
3 Yr 16.2%* -14.0% 28.3% 9.17%
5 Yr 9.0%* -11.5% 15.4% 8.65%
10 Yr 16.8%* -1.8% 16.8% 1.14%

* Annualized

Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
2018 -7.9% -25.3% 21.5% 56.76%
2017 21.1% -10.8% 43.9% 30.28%
2016 -13.4% -31.6% 6.9% 38.68%
2015 -0.8% -20.4% 13.8% 33.98%
2014 22.3% -5.8% 31.5% 21.88%

Total Return Ranking - Trailing

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
YTD 26.1% 3.4% 49.1% 21.37%
1 Yr 13.0% -12.6% 38.1% 31.62%
3 Yr 16.2%* -14.0% 28.5% 13.76%
5 Yr 9.0%* -11.5% 17.0% 18.27%
10 Yr 16.8%* -1.8% 18.0% 11.36%

* Annualized

Total Return Ranking - Calendar

Period JNGLX Return Category Return Low Category Return High Rank in Category (%)
2018 -7.9% -25.3% 22.2% 63.06%
2017 22.6% -10.8% 45.8% 29.36%
2016 -13.1% -26.4% 8.7% 54.72%
2015 8.2% -16.6% 15.2% 30.10%
2014 35.4% -5.8% 36.7% 2.08%

NAV & Total Return History


Holdings

JNGLX - Holdings

Concentration Analysis

JNGLX Category Low Category High JNGLX % Rank
Net Assets 4.02 B 3.25 M 47.5 B 16.54%
Number of Holdings 94 26 388 35.43%
Net Assets in Top 10 1.15 B 913 K 17.4 B 20.47%
Weighting of Top 10 32.15% 21.3% 77.1% 91.34%

Top 10 Holdings

  1. Merck & Co Inc 4.61%
  2. Novartis AG ADR 4.34%
  3. Abbott Laboratories 3.70%
  4. AstraZeneca PLC 3.26%
  5. Thermo Fisher Scientific Inc 3.09%
  6. UnitedHealth Group Inc 2.87%
  7. Bristol-Myers Squibb Company 2.65%
  8. Takeda Pharmaceutical Co Ltd 2.64%
  9. Sanofi SA 2.54%
  10. Boston Scientific Corp 2.44%

Asset Allocation

Weighting Return Low Return High JNGLX % Rank
Stocks
97.28% 90.21% 103.54% 71.65%
Other
1.87% -27.41% 5.17% 7.87%
Cash
0.46% 0.00% 9.79% 73.23%
Convertible Bonds
0.35% 0.00% 1.54% 3.15%
Bonds
0.04% 0.00% 20.60% 3.94%
Preferred Stocks
0.00% 0.00% 1.08% 50.39%

Stock Sector Breakdown

Weighting Return Low Return High JNGLX % Rank
Healthcare
95.90% 56.22% 99.75% 64.57%
Technology
0.89% 0.00% 16.35% 14.17%
Utilities
0.00% 0.00% 0.00% 39.37%
Real Estate
0.00% 0.00% 5.81% 44.88%
Industrials
0.00% 0.00% 2.40% 46.46%
Financial Services
0.00% 0.00% 5.93% 49.61%
Energy
0.00% 0.00% 0.43% 43.31%
Communication Services
0.00% 0.00% 1.02% 43.31%
Consumer Defense
0.00% 0.00% 34.83% 44.88%
Consumer Cyclical
0.00% 0.00% 10.49% 44.88%
Basic Materials
0.00% 0.00% 1.94% 55.12%

Stock Geographic Breakdown

Weighting Return Low Return High JNGLX % Rank
US
76.56% 58.61% 99.93% 70.87%
Non US
20.72% 0.00% 40.52% 25.20%

Bond Sector Breakdown

Weighting Return Low Return High JNGLX % Rank
Cash & Equivalents
0.46% 0.00% 9.79% 78.81%
Corporate
0.39% 0.00% 21.46% 14.41%
Derivative
0.00% -0.06% 0.00% 33.05%
Securitized
0.00% 0.00% 0.00% 38.14%
Municipal
0.00% 0.00% 0.00% 38.14%
Government
0.00% 0.00% 0.20% 38.98%

Bond Geographic Breakdown

Weighting Return Low Return High JNGLX % Rank
US
0.04% 0.00% 19.07% 3.15%
Non US
0.00% 0.00% 3.76% 41.73%

Expenses

JNGLX - Expenses

Operational Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.82% 0.10% 4.94% 82.05%
Management Fee 0.64% 0.09% 1.30% 42.52%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.12% 0.01% 0.40% 50.00%

Sales Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee 2.00% 0.75% 2.00% 24.39%

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

JNGLX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 36.00% 0.00% 341.00% 42.37%

Distributions

JNGLX - Distributions

Dividend Yield Analysis

JNGLX Category Low Category High JNGLX % Rank
Dividend Yield 0.00% 0.00% 5.43% 48.03%

Dividend Distribution Analysis

JNGLX Category Low Category High Category Mod
Dividend Distribution Frequency Semi-Annually Annually Quarterly Annually

Net Income Ratio Analysis

JNGLX Category Low Category High JNGLX % Rank
Net Income Ratio 0.48% -2.24% 2.12% 15.38%

Capital Gain Distribution Analysis

JNGLX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

JNGLX - Fund Manager Analysis

Managers

Andrew Acker


Start Date

Tenure

Tenure Rank

May 01, 2007

12.59

12.6%

Andy Acker is a Portfolio Manager at Janus Henderson Investors responsible for managing the Global Life Sciences and Biotechnology strategies since 2007 and 2018, respectively. He also leads the firm’s Health Care Sector Research Team. Andy was assistant portfolio manager on the Global Life Sciences strategy from 2003 to 2007. He joined Janus in 1999 as a research analyst focused on companies in the biotechnology and pharmaceutical industries. Prior to this, he worked as a strategy consultant for the Boston Consulting Group and as a health care analyst for Morgan Stanley Venture Partners. Andy received his bachelor of science degree in biochemical sciences from Harvard University, graduating magna cum laude and Phi Beta Kappa. He also earned an MBA with honours from Harvard Business School. Andy holds the Chartered Financial Analyst designation.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.34 22.22 9.78 19.59